APA (7th ed.) Citation

S, A., PCL, F., B, B., G, P., F, R., CS, A., . . . T, P. (2025). Utility of plasma GFAP as a secondary endpoint for clinical trials in Alzheimer's disease. The journal of prevention of Alzheimer's disease, 12(7), 100205. https://doi.org/10.1016/j.tjpad.2025.100205

Chicago Style (17th ed.) Citation

S, Abbas, et al. "Utility of Plasma GFAP as a Secondary Endpoint for Clinical Trials in Alzheimer's Disease." The Journal of Prevention of Alzheimer's Disease 12, no. 7 (2025): 100205. https://doi.org/10.1016/j.tjpad.2025.100205.

MLA (9th ed.) Citation

S, Abbas, et al. "Utility of Plasma GFAP as a Secondary Endpoint for Clinical Trials in Alzheimer's Disease." The Journal of Prevention of Alzheimer's Disease, vol. 12, no. 7, 2025, p. 100205, https://doi.org/10.1016/j.tjpad.2025.100205.